NeuroPace (NPCE)
(Delayed Data from NSDQ)
$6.77 USD
-0.51 (-7.01%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $6.79 +0.02 (0.30%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
NPCE 6.77 -0.51(-7.01%)
Will NPCE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NPCE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NPCE
Neuronetics (STIM) Reports Q2 Loss, Lags Revenue Estimates
Avinger (AVGR) Reports Q2 Loss, Lags Revenue Estimates
NPCE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Waters (WAT) Q2 Earnings and Revenues Top Estimates
Globus Medical (GMED) Q1 Earnings and Revenues Beat Estimates
Thermo Fisher Scientific (TMO) Tops Q1 Earnings and Revenue Estimates
Other News for NPCE
Morgan Stanley Sticks to Its Hold Rating for NeuroPace (NPCE)
Wells Fargo Sticks to Its Buy Rating for NeuroPace (NPCE)
NeuroPace price target lowered by $5 at Wells Fargo, here's why
NeuroPace Inc (NPCE) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue Growth Amidst ...
NeuroPace Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance